Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Exploratory research project aims to develop novel protein expression systems via cell reprogramming

Cambridge, UK, 11 January 2021: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, and the MRC Laboratory of Molecular Biology (LMB), a world-class research laboratory dedicated to understanding important biological processes at the molecular level, today announced an exploratory research collaboration. The project aims to develop novel protein expression systems by leveraging recent advances in direct cell reprogramming to help improve the production of proteins which are not produced sufficiently well in existing expression systems. More>>

Nova Biomedical FLEX2 Cell Culture Analyzer

Adds Sample Retain Capability

Waltham, MA–Nova Biomedical announces the addition of a Sample Retain Collector (SRC) for BioProfile FLEX2 cell culture analyzer. The FLEX2 automated cell culture analyzer measures up to 16 tests including pH, gases, metabolites, osmolality, cell density, and cell viability. A single FLEX2 analyzer with SRC and the previously introduced Online Sampler (OLS) module provides automated sampling and analysis of these key cell culture tests from as many as 10 bioreactors. This FLEX2 automation package saves hours of time versus manual sampling, analysis, sample storage, and after-hours cell culture monitoring. More>>

Etihad Cargo Reports 50% Y-O-Y Rise in Pharma Shipments

Carrier operates across more than 1,050 pharma trade lanes and counts 54 dedicated pharma stations in its global network. Etihad Cargo, the cargo and logistics arm of Abu Dhabi-based Etihad Aviation Group, has reported a 50 per cent year-on-year rise in pharma shipments under its specialised PharmaLife product. More>>

The biotech company baseclick GmbH launched a new and highly efficient method for SARS-CoV-2 mutation analysis

The rapid spread of the newly emerging SARS-CoV-2 virus variant B.1.1.7 in Great Britain and other countries shows changes in the genome of the SARS-CoV-2 virus can lead to new biological properties. More>>

Join Us In A New Free Webinar by Qloud

Our experience in qualifications has allowed us to identify the necessary improvements for the resolution of data integrity GAPs, and process optimization in regulated environments. More>>

PHASTAR Announces Investment by Charterhouse Capital Partners

Funding will Support Expansion of Statistics and Data Science Services and Geographic Reach

PHASTAR, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support PHASTAR’s growth in biometrics and geographic expansion. Charterhouse is making its investment in partnership with PHASTAR’s Founder and CEO Kevin Kane, who remains a significant shareholder in the business. Kevin and the existing management team will continue to run, manage and operate the business on a day-to-day basis. More>>

Calyx Supports Breakthrough Therapy Approvals for Oncology Treatments

Calyx Medical Imaging and other eClinical services provide critical support for clinical development programs to deliver much-needed therapies to market

Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that its Medical Imaging and other eClinical solutions supported half of the oncology treatments approved by the FDA as Breakthrough Therapies in the past two years. More>>

BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL BIOMARKERS OF COGNITIVE HEALTH USING APPLE WATCH AND IPHONE

January 11, 2021 at 7:30 AM EST

The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease Cognitive health — the ability to think clearly, to learn and to remember — is an indicator of brain health and important to performing daily activities More>>

EQRx Scales Disruptive Model of Important New Medicines at Lower Prices with $500M Series B Financing

Funding accelerates development of late-stage cancer therapies, pipeline expansion and business growth Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers More>>

Servier and X-Chem Announce Drug Discovery Collaboration in Neurological Diseases

Funding accelerates development of late-stage cancer therapies, pipeline expansion and business growth Syndicate includes all Series A investors, preeminent life science and generalist funds, and market-leading health systems and payers More>>